Group items tagged

The UK Health Security Agency (UKHSA) has suggested that the Live Attenuated Influenza Vaccine (LAIV) vaccine that offers protection to children against flu may also help reduce the rate of group A strep infections. LAIV is a nasal spray offered each season to most children aged 2 and 3 years old, and to school-aged children, to help protect against flu. The new study looked back at data from 2013 to 2017, comparing rates of group A strep (GAS) infections in pilot areas and comparing them to other areas where the vaccine was not being offered as widely. It was found that incidence of GAS was lower in pilot areas where the LAIV vaccine was being offered to all primary school children, compared to areas where it was being incrementally rolled out. The study revealed, in 2 to 4 year olds, rates of GAS were 73.5 per 100,000 children in pilot areas, compared to 93 per 100,000 children in non-pilot areas. In 5 to 10 year olds, rates of GAS were 50.3 per 100,000 children in pilot areas, compared to 57.8 per 100,000 in non-pilot areas.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.

The National Health Service (NHS) is embracing new technology and innovations like artificial intelligence (AI) to reduce the number of missed hospital appointments and improve waiting times for elective care. Following a successful pilot in Mid and South Essex NHS Foundation Trust, the health service is set to roll out AI software to 10 more trusts across England in the coming months. The software, developed by Deep Medical in collaboration with a frontline worker and NHS clinical fellow, helps reduce the number of missed appointments by offering patients convenient time slots and backup booking options. Since the AI programme was piloted six months ago, Mid and South Essex NHS Foundation Trust has seen a 30 per cent fall in non-attendances. During the pilot period, a total of 377 did not attends (DNAs) were prevented and an additional 1,910 patients were attended.

"Patients deserve choice, but wherever they go they will find vacant nursing posts and overstretched services," responded Professor Pat Cullen, RCN General Secretary and Chief Executive, to the introduction of the new pilot scheme for out-of-hospital patient care. The NHSE and the DHSC have announced a new pilot scheme commencing in autumn "offering patients a choice of where they receive out-of-hospital care". Under the initiative, individuals requiring treatment outside of hospitals will have the opportunity to select from a range of providers across both the NHS and the independent sector. Patients can select their care provider for in-hospital consultant-led services post-GP consultation, offering a choice from at least 5 providers with details on waiting times, distance, and quality.

The program's overall goal is to give practices the motivation, support, and infrastructure needed to deliver coordinated, high-quality care within the current work environment. Initially, the Blueprint model was pilot tested in three areas and now serves more than half the state's residents in 14 communities. Early trends in the pilot communities suggest that the program has reduced utilization and growth in health care spending and improved the provision of appropriate care and services.

Local pharmacists in England can now evaluate and provide treatment for patients with uncomplicated urinary tract infections (UTIs) in women under the age of 65, without the need for a GP appointment. The 'ByeByeUTI' scheme has been expanded across the country, following a successful pilot across North East and North Cumbria. More than 30,000 women have been treated for uncomplicated urinary tract infections at local pharmacies since the pilot scheme was launched in July 2022 as part of the NHS and government's primary care access recovery plan, according to NHS England. The expansion of pharmacy services not only enhances patients' access to care but also frees up tens of thousands of GP appointments at the same time. Dr Faisel Baig, Medical Director for Primary Care, NHS England North East and Yorkshire, said that the rollout of this service across the whole region will enable many more women to receive "faster and easier" access to advice and treatment.

The NHS has launched plans to expand pioneering subscription-style drug contracts to develop lifesaving antibiotics of the future. It is building on its world-first pilot to incentivise the pharmaceutical industry to develop new antibiotics that could be offered to NHS patients when they need them the most. The consultation has launched almost a year to the day that contracts for two superbug-busting drugs were rolled out as part of a world-first pilot. Cefiderocol and ceftazidime-avibactam, new antibiotics manufactured by Shionogi and Pfizer respectively, were awarded world-first subscription contracts which provided the companies with a fixed annual fee based primarily on the availability of the drugs and their value to the NHS, as opposed to the volumes used. By breaking the link between the payments companies receive and the number of their antibiotics prescribed, the NHS is removing any incentive to overuse antibiotics, decreasing the risk of life-threatening infections, such as sepsis and pneumonia, becoming resistant to treatment.

The Medicines and Healthcare products Regulatory (MHRA) and Genomics England to launch a brand-new genetic research resource, known as a 'biobank' on Thursday (June 01) to tackle the issue of Adverse Drug Reactions (ADRs). Biobank will help to better understand how a patient's genetic makeup can impact the safety of their medicines. "The Yellow Card biobank, which will contain genetic data and patient samples, will operate alongside the MHRA's Yellow Card reporting site for suspected side effects and adverse incidents involving medicines and medical devices," said MHRA. The biobank pilot will officially begin on 1 June 2023 with participant recruitment commencing later this year, on 1 September. The sequencing of participants' genetic material will begin in Spring 2024, with initial research findings from the pilot due to be published in 2025. Genomics England will be supporting the MHRA with sequencing and storage of genetic material through use of their well-established and secure infrastructure.

A new study by the University of East Anglia has found that giving out 'vape starter kit vouchers' on the NHS could help even hardened smokers quit. In the recent study, researchers worked with GPs and the 'NHS stop smoking service', commissioned locally by Public Health at Norfolk County Council, to set up a pilot 'vape shop voucher' scheme (worth £25 each) to help patients who had tried but failed to stub it out in the past. An evaluation of the scheme, funded by Norfolk County Council, showed it was a big success - with 42 per cent of the entrenched smokers who were referred to it and redeemed their vape voucher having quit within a month. After the success of the pilot, the scheme has been rolled out across Norfolk and the research team hope it could be rolled out nationally to help more smokers quit. Lead researcher and addiction expert Prof Caitlin Notley, from the UEA's Norwich Medical School, said: "Research shows that vaping is an effective way of quitting smoking, compared to nicotine replacement therapies like patches and gum. E-cigarettes or vapes are now the most popular way of stopping smoking.

The Scottish government is planning to publish its review report on use of automated technology in community pharmacies by the end of 2023. The technology being trialled as part of the pilot includes robotic process automation, automated medicine storage systems, barcode scanners and prescription collection kiosks. The evaluation, which started prior to the COVID-19 pandemic, is due to be completed at the end of November 2023. Patricia Findlay, professor of work and employment relations at the University of Strathclyde, who was commissioned to produce the report, told The Pharmaceutical Journal that the pilot pharmacies taking part in the scheme are all based in Scotland, but she didn't reveal their names.

Community pharmacies in England could soon be allowed to make cancer referrals to hospitals under new plans to improve early detection of the disease. An NHS pilot scheme, which starts later this year as a pilot in an undisclosed number of places of England, will see community pharmacy staff spotting signs of cancer in people who might not have noticed symptoms. Pharmacy teams will be trained to spot red flags, such as patients with symptoms such as a cough that lasts for three weeks or more, difficulty swallowing or blood in their urine, and send them for scans and checks without needing to see a GP if they think it could be cancer. Amanda Pritchard, the NHS chief executive, will unveil the plans at the NHS Confed Expo conference in Liverpool on Wednesday (June 15), and say: "These plans have the power to truly transform the way we find and treat cancer, and ultimately spare thousands of patients and their families from avoidable pain and loss." The plans include new "roaming liver trucks" - which will be parked near GP surgeries, in town centres and food banks - to encourage people most at risk of getting liver cancer to get "on the spot scans" for diagnosis.

NHS England has launched a cloud-based platform that links recently-retired consultants, who still hold a licence to practice, with secondary care providers who need additional help with their waiting lists. It has been developed to make it easier and more flexible for retired doctors to return to the health service as part of the Long Term Workforce Plan. NHS chief executive Amanda Pritchard in June 2023 announced the NHS Emeritus pilot scheme, which is expected to help reduce long waits for elective care. Initially, the scheme will run for a year across England, and if successful, it may be expanded to cover other work areas. Health Minister Andrew Stephenson commented: "Returning consultants will bring invaluable experience and knowledge, and the new digital platform will match highly-skilled consultants with the NHS trusts that require their expertise, providing high quality care and alleviating pressures on high demand areas.

At their recent online briefing, DAUK's GP committee outlined a comprehensive 10-point plan designed to relieve pressure on GPs, improve access, reduce mortality rates, lower hospital admissions, and enhance patient satisfaction. DAUK's manifesto advocates reallocating resources, including the Additional Roles Reimbursement Scheme (ARRS), currently directed towards Pharmacy First and acute care hub pilots, amounting to £2 billion. This strategic reallocation aims to enhance primary care capacity and reduce reliance on acute services. Dr Lizzie Toberty, DAUK's GP lead, emphasised the critical need for patients to have timely access to GPs who understand their needs, stating, "We need patients to be able to see a GP who knows them and understands their needs in a timely way wherever possible." She highlighted DAUK's vision to restore general practice as the cornerstone of the NHS through practical, achievable solutions.

Novo Nordisk has launched PenCycle, a recycling initiative for pre-filled injection pens, designed to address the challenge of recycling injection pen devices. A first-of-its-kind scheme in the UK, covering FlexPen® and FlexTouch® used to dispense insulin and other medications, will have community pharmacies playing a key role. Users can return their devices to local participating community pharmacies or through pre-paid Royal Mail boxes or use an 'at home' collection pilot service for growth hormone pens. The pens will then be returned to Denmark where the plastic will be recycled into a range of items, such as chairs and lamps, the Danish multinational pharmaceutical company said.

Scotland has become the world's first country to introduce a simple blood test for Type 1 diabetes patients, enabling them to stop taking insulin by improving the accuracy of diagnosis. The routine C-peptide test, introduced today (November 1), will allow doctors to know how much insulin someone with diabetes is making themselves. The roll-out of test follows a two-year pilot study in NHS Lothian led by diabetes and endocrinology consultant Professor Mark Strachan. Strachan said: "C-peptide helps diabetes specialists make a more accurate diagnosis of the cause of diabetes, and that means we can get people on the most appropriate treatment. In some instances, C-peptide testing allowed people to stop very long-standing insulin therapy; this can be life-transforming."

The Home Affairs Committee has called upon the government to revise its current drug policy, moving away from the exclusive 'abstinence only' approach towards a more practical strategy that highlights harm reduction. The HAC's recommendations also include the introduction of a national naloxone programme in England, with community pharmacies playing a central role in facilitating access. The committee published its comprehensive report on August 31, with key recommendations, including the 'urgent' reclassification of psychedelic drugs for therapeutic research; a pilot safe consumption facility program (long resisted by the Westminster Government despite Scottish lobbying); and enhanced provision and research on cannabis-based medicinal products (CBPMs). The report urged the establishment of a national naloxone programme in England, aligning with devolved nations. It also highlighted the role of community pharmacists and peer initiatives for effective distribution and administration. Furthermore, the report emphasises enhanced naloxone distribution for prison leavers. Naloxone is a medication capable of rapidly reversing heroin or methadone overdoses, potentially saving lives.

Pharmanovia, a global pharmaceutical company has announced increased targets to divert 40 per cent of its air shipments to sea in 2023, and 75 per cent by the end of 2028. It has made the pledge as it revealed the significant progress made towards achieving its ambitious science-backed ESG initiatives in its new Sustainability Report. Its industry-leading air-to-sea pilot scheme, which focused on its Spain-to-Australia freight route, cut an estimated 470,000kg in potential CO2 emissions in 2022 - reducing Scope 3 upstream transport emissions by 18 per cent. This initiative demonstrates Pharmanovia's role as an industry leader on carbon reduction and follows a recent report which stated just 16 of 500 pharmaceutical companies measured their entire Scope 3 emissions. The new Sustainability Report reveals that the Scope 2 emissions decreasing by 13 per cent in 2022, due to lower direct electricity demand within the office space. The company's packaging audit seeing a 52 per cent increase in the percentage of products packed with at least one fully recyclable component, up from 12% in 2021 to 64 per cent in 2022 Strong progress in an initiative which saw Pharmanovia set ESG goals all employees across its global offices as part of annual performance awards. Employees achieved a 98 per cent completion rate of the compliance training, including ESG modules

Boots has partnered with Uber Eats to deliver beauty essentials and healthcare products to customers' doors in 30 minutes. Medicines for minor ailments such as coughs, colds, hay fever, mild pain, rashes as well as COVID-19 test kits can be ordered through Uber Eats. Boots is partnering with the doorstep delivery company with a pilot in 14 of its stores around the UK, with 13 of those stores giving customers within range access to third-party doorstep delivery of Boots products for the very first time. Uber Eats customers within range of participating Boots stores can choose from more than 900 products available for delivery straight to their homes or workplace, including toiletries, medicines for minor ailments, food and drink options, and best-selling beauty and gifting options perfect for a last-minute gift or treat. Paula Bobbett, Chief Digital Officer at Boots said: "We are hugely excited to be launching our partnership with Uber Eats. As the first health and beauty retailer on its platform, we can offer an extensive range of product options to customers for delivery straight to their door. Whether it's medicines for mild illnesses or last-minute gifts, beauty items or top-ups of a favourite skincare brand, we can meet all our customers' needs both quickly and conveniently."

The Community Pharmacist Consultation Service (CPCS) will be expanded to enable urgent and emergency care settings to refer patients to a community pharmacist for a consultation for minor illness or urgent medicine supply from Monday (15 May), the DHSC and NHSE said. The service builds on the progress made in GP referrals via the CPCS and hospital referrals under the Discharge Medicine Service. It was originally planned to launch in March, and fee for this service will be the existing CPCS fee of £14, as per the agreement for both year 4 and year 5 of the Community Pharmacy Contractual Framework (CPCF) 2019 to 2024 5-year deal. In an update on the CPCF, published today (12 May), the Department of Health and Social Care (DHSC) and NHS England (NHSE) has also committed to the 4 October 2023 launch date for the Tier 2 of the Pharmacy Contraception Service, subject to a positive evaluation of the pilot. The Tier 1 of the service was launched on 24 April, delayed by over three months. This new service enables community pharmacists to provide ongoing management, via a patient group direction (PGD), of routine oral contraception that was initiated in general practice or by a sexual health clinic. The fees for this service are as follows: a fee for each consultation of £18; and a set-up fee of £900, paid in instalments. The Tier 2 will "enable community pharmacists to also initiate oral contraception, via a PGD, and provide ongoing clinical checks and annual reviews," Alette Addison, deputy director for pharmacy, dental and optical at the DHSC and Ali Sparke, director for dentistry, community pharmacy and optometry at the NHSE, said in a letter.